Wealthspire Advisors (New York)’s Recursion Pharmaceuticals RXRX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.5K	Sell	12,535 -300	-2%	-$1.16K	﹤0.01%	913
2025 Q4	$52.5K	Sell	12,835 -231	-2%	-$1.14K	﹤0.01%	1024
2025 Q3	$63.8K	Sell	13,066 -927	-7%	-$4.87K	﹤0.01%	1152
2025 Q2	$70.8K	Buy	13,993 +1,508	+12%	+$7.41K	﹤0.01%	831
2025 Q1	$66K	Hold	12,485	–	–	﹤0.01%	771
2024 Q4	$84.4K	Buy	12,485 +1,158	+10%	+$7.79K	﹤0.01%	772
2024 Q3	$74.6K	Sell	11,327 -1,000	-8%	-$7.17K	﹤0.01%	732
2024 Q2	$92.5K	Buy	12,327 +1,000	+9%	+$8.72K	﹤0.01%	642
2024 Q1	$113K	Hold	11,327	–	–	﹤0.01%	624
2023 Q4	$112K	Hold	11,327	–	–	﹤0.01%	631
2023 Q3	$86.7K	Buy	+11,327	New	+$113K	﹤0.01%	582

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wealthspire Advisors (New York)'s RXRX Position: Q1 2026 in Review

Wealthspire Advisors (New York) reduced its Recursion Pharmaceuticals (RXRX) stake by 2.3% in Q1 2026, selling an estimated $1.16K and leaving 12,535 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #913.

Wealthspire Advisors (New York) first reported a position in RXRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $113K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Wealthspire Advisors (New York) held 12,535 shares of Recursion Pharmaceuticals worth $38.5K as of Q1 2026.
Wealthspire Advisors (New York) sold 300 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.16K.
Recursion Pharmaceuticals made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #913 holding.
Wealthspire Advisors (New York) first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Wealthspire Advisors (New York)'s Recursion Pharmaceuticals position peaked at $113K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.